正清风痛宁联合塞来昔布治疗盘源性腰痛的临床观察

Clinical observation of Zhengqing fengtongning combined with celecoxib in the treatment of discogenic low back pain

摘要:

目的：观察正清风痛宁治疗腰椎间盘突出症的临床疗效及安全性。方法：100例腰椎间盘突出症患者,采用随机数字法分为观察组和对照组,每组50例,对照组口服塞来昔布胶囊；实验组在口服塞来昔布胶囊的基础上加用正清风痛宁缓释片。观察两组患者分别在治疗前及第1、2、4、8周疼痛VAS评分(visual analogue scale, VAS)、Oswestry功能障碍指数(Oswestry disability index, ODI )及不良反应。结果:治疗后两组的VAS评分较治疗前都有明显的下降,且治疗后实验组每个时间点的VAS评分及ODI指数较对照组都有明显的降低(P＜0.05)；两组不良反应发生率比较无统计学差异。结论：正清风痛宁可以治疗腰椎间盘突出症,无相关不良反应,值得在临床推广。

Abstract:

Objective: To observe the clinical efficacy and safety of Zheng Qing Feng Tong Ning in the treatment of Lumbar disc herniation. Methods: 100 patients with Lumbar disc herniation were randomly divided into two groups, the control group (n=50): oral celecoxib capsules; experimental group (n=50): oral celecoxib capsules on the basis of adding Zhengqing Fengtongning sustained-release tablets. Visual analogue scale (VAS), Oswestry disability index (ODI) and adverse reactions were observed before treatment and at week 1, 2, 4 and 8 respectively. Results: After treatment, the VAS scores of the two groups were significantly lower than those before treatment, and the VAS scores and ODI index of the experimental group were significantly lower than those of the control group at each time point after treatment (P < 0.05). Conclusion: Zhengqing Fengtongning can treat Lumbar disc herniation without related adverse reactions, which is worthy of clinical promotion.